Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Recent advances in electric-stimulus assisted microneedle patches for skin disease treatment

Tao XN., Yao L., Cheng X., Xiang XW., Qiu J., Zhao H.

Narrative Review on Systemic / IV, published in J Nanobiotechnology (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
J Nanobiotechnology (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41272674
PMCID
PMC12640005
DOI
10.1186/s12951-025-03835-8

Abstract (original English)

Due to the natural barrier of skin structure, traditional topical drug utilization for skin disease management has been severely constrained by low bioavailability. While current microneedle (MN)-based systems confront challenges related to therapeutic efficacy, penetration depth, and delivery precision, they offer considerable promise as minimally invasive platforms. To address these limitations, electric stimulus (ES) has been strategically integrated as a programmable external trigger within microneedle patches, enabling spatiotemporal control over drug release kinetics. This review systematically delineates recent advancements in ES-assisted microneedle systems for managing dermatological conditions, highlighting their dual capacity to enhance transdermal permeability while minimizing systemic toxicity through localized delivery, in alignment with emerging trends in functional integration and device miniaturization. This encompasses a comprehensive analysis of the regulatory role of ES, strategic selection of power supply modules, and the rational design of microneedles in conjunction with their corresponding drug-loading strategies. Guided by the Three I Principles (Integrated-Intelligent-Individualized), future developments should focus on creating closed-loop systems with embedded biosensors for real-time biomarker monitoring, implementing AI-driven adaptive dosing algor

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsHumansSkin DiseasesDrug Delivery SystemsAdministration, CutaneousMicroinjectionsElectric StimulationNeedlesTransdermal Patch

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research